Immunic presents data from phase 1b clinical trial of imu-856 in celiac disease at the united european gastroenterology week 2023

New york , oct. 15, 2023 /prnewswire/ --  immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the presentation of data from the company's phase 1b clinical trial of imu-856, an orally available and systemically acting small molecule modulator that targets sirt6 (sirtuin 6), in patients with celiac disease in a moderated poster session at the united european gastroenterology week (uegw) 2023, taking place october 14-17 in copenhagen. in this phase 1b, double-blind, randomized, placebo-controlled trial in patients with celiac disease, imu‑856 showed positive effects over placebo in four key dimensions of clinical outcome: protection of the gut architecture, improvement of patients' symptoms, biomarker response and enhancement of nutrient absorption.
IMUX Ratings Summary
IMUX Quant Ranking